On May 28, 2026 Anaveon, a late-stage preclinical biotechnology company focused on reprogramming the immune system for the treatment of autoimmune and inflammatory diseases, reported that new clinical data from its legacy oncology asset ANV600 (sunekafusp alpha) will be presented at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Following its strategic pivot to immunology, Anaveon is actively seeking global development and commercialization partners for its oncology portfolio to maximize the potential of these highly differentiated assets.

ANV600 is a first-in-class, non-blocking PD-1-targeted IL-2R-βγ agonist designed to selectively expand tumor-reactive PD-1+ CD8+ effector T cells while reducing the toxicities historically associated with IL-2 therapy. It is compatible with existing Check Point Inhibitors (CPI) and is positioned for use in CPI-resistant and CPI-relapsed patients.

Key results from the EXPAND-1 Phase 1 study will be highlighted in the poster:

The encouraging preliminary antitumor activity observed with ANV600 should be investigated further through additional clinical studies with larger patient populations,
ANV600 is well tolerated as a monotherapy and in combination with pembrolizumab,
A complete response (CR) was observed in a patient with NSCLC (non-small cell lung cancer) previously progressing on CPI and treated with ANV600 monotherapy at 120 µg/kg Q2W. Partial responses (PRs) were reported for two patients treated respectively with 30 µg/kg and 60 µg/kg ANV600 Q2W in combination with pembrolizumab Q3W,
Patients experienced target lesion shrinkage in 29% of patients receiving ANV600 monotherapy and 24% of patients receiving ANV600 plus pembrolizumab,
Disease control defined as Complete Response, Partial Response, or Stable Disease observed in 42% of patients treated with ANV600 monotherapy and 59% of the patients receiving ANV600 and Pembrolizumab,
Recommended Phase 2 dose of 90 µg/kg weekly for 4 weeks followed by 150 µg/kg Q2W established,
Patients Treatment with ANV600 resulted in higher absolute counts of CD8+ T cells and NK cells over regulatory T cells.
"Patients with advanced solid tumors treated with ANV600 derived meaningful clinical benefit, with approximately 24% of patients achieving a Complete Response, Partial Response or durable Stable Disease maintained for at least 18 weeks (≥3 tumor assessments)," said Prof. Dr. med. Markus Jörger of Health Ostschweiz (HOCH) in St. Gallen (Switzerland). "The trial provided a valuable treatment option for patients whose disease had progressed beyond available therapies. ANV600 demonstrated a promising safety-efficacy profile, together with compelling proof-of-mechanism in patients with advanced solid tumors."

ASCO Annual Meeting abstracts may be accessed online via View Source

Presentation Details:
Title: Safety, PK/PD, and efficacy results from Expand-1: A phase 1 dose escalation study of the novel PD-1 targeted IL-2R-βγ agonist sunekafusp alpha (ANV600) as a single agent and in combination with pembrolizumab in patients with advanced solid tumors.
First Author: Markus Joerger
Abstract number: 2587
Session Title: Development Therapeutics- Immunotherapy
Poster board: 377
Location, Date and Time: Hall A, May 30, 2026, 1:30 to 4:30 pm, CDT

"With established clinical benefits and strong interest from current clinical investigators, we believe that ANV600 is ideally suited for a partner with the resources and expertise to bring it forward in CPI-resistant NSCLC and other immuno-oncology indications," added Thaminda Ramanayake, Chief Executive Officer of Anaveon.

Anaveon’s proprietary oncology product portfolio is built around a non-blocking PD-1 targeted cytokine platform. This highly selective "cis-signaling" proximity-activated delivery of cytokines is precise and combinable with Check Point Inhibitors. In addition to ANV600, the platform includes ANV700, a preclinical proximity-activated PD-1-targeted IL-21 fusion protein with potential for synergistic effects when combined with IL-2-based approaches and another undisclosed preclinical program. Included in the oncology portfolio is ANV419, an earlier generation (non-PD-1-targeted) IL-2/anti-IL-2 fusion protein with demonstrated safety in prior clinical studies.

The company is now prioritizing its core immunology pipeline and is open to various partnering structures (license, co-development, or acquisition) for the oncology platform and portfolio.

(Press release, Anaveon, MAY 28, 2026, View Source [SID1234666183])

On May 28, 2026 BPGbio, Inc., a clinical-stage biopharmaceutical company advancing mitochondrial-targeted therapeutics for patients, reported that new clinical progress from its ongoing Phase 2 study of BPM31510 in newly diagnosed glioblastoma multiforme (GBM) will be presented at the upcoming ASCO (Free ASCO Whitepaper) Annual Meeting.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The trial-in-progress poster will be presented by Seema Nagpal, M.D., Principal Investigator of the study and Professor of Neurology and Neurological Sciences at Stanford Medicine.

Abstract Details

Abstract Number: TPS2101
Title: Progress report of a phase 2 study of BPM31510 (a lipid nano dispersion of oxidized CoQ10) with vitamin K in combination with standard of care (SOC) RT and TMZ in glioblastoma multiforme (GBM) patients without prior therapy
Session Type/Title: Poster Session – Central Nervous System Tumors
Poster Board: 461b
Presentation Date & Time: Monday, June 1, 2026 | 1:30 PM – 4:30 PM CDT

The ongoing Phase 2 study is evaluating BPM31510, an investigational lipid nanodispersion formulation of oxidized Coenzyme Q10 (CoQ10), administered with vitamin K1 in combination with standard-of-care radiation therapy (RT) and temozolomide (TMZ) in patients with newly diagnosed GBM who have not received prior therapy.

BPM31510 is designed to target dysregulated mitochondrial metabolism in cancer cells. By modulating mitochondrial function and restoring oxidative balance, BPM31510 aims to induce tumor-selective redox stress while helping preserve healthy tissue metabolism. The investigational therapy seeks to re-engage mitochondrial pathways that may contribute to tumor cell vulnerability in highly aggressive cancers such as glioblastoma. Moreover, the direct targeting of the BCL-2 protein family serves to sensitize patients to radiotherapy.

"The BPM31510 phase I trial delivered pharmacodynamic proof, PET-confirmed reversal of the Warburg effect, shifting tumor metabolism from glycolysis to oxidative phosphorylation at supraphysiologic CoQ10 concentrations. That metabolic reprogramming drives a ROS-mediated, BCL-2–dependent apoptotic cascade that may finally unlock glioblastoma’s mitochondrial vulnerability", said Vivek Subbiah, M.D., Jeffrey and Christina Bird Endowed Chair and Professor of Medicine, Division of Oncology and Associate Director for Drug Development and Precision Oncology at the Stanford Cancer Institute, Stanford University School of Medicine, CA, USA. "For patients with GBM, a devastating disease where median survival remains under two years despite decades of research, the ongoing front-line study is a test of whether this science can translate into a meaningful survival benefit."

Glioblastoma is the most common and aggressive malignant primary brain tumor in adults and is associated with poor survival despite multimodal treatment approaches. Increasing evidence suggests that altered mitochondrial metabolism plays a critical role in glioblastoma progression, treatment resistance, and tumor adaptation.

The ongoing Phase 2 study builds upon prior clinical and translational research evaluating BPM31510 across oncology indications and reflects BPGbio’s broader focus on targeting mitochondrial dysfunction in diseases with significant unmet medical need.

"Glioblastoma remains one of the most devastating cancers, with limited therapeutic advances for patients in recent decades," said Niven R. Narain, Ph.D, President and Chief Executive Officer of BPGbio. "We believe mitochondrial targeting represent an important and underexplored therapeutic frontier in GBM in oncology. BPM31510 is designed to target the mitochondrial metabolism that cancer cells depend upon, increasing OXPHOS and ROS, restoring apoptotic potential to a cancer cell. The emerging data in this study is encouraging, and we look forward to sharing updates with the community at ASCO (Free ASCO Whitepaper)."

About BPM31510
BPM31510 is an investigational first-in-class mitochondrial therapeutic consisting of a lipid nano dispersion formulation of oxidized CoQ10 designed to modulate mitochondrial metabolism. BPM31510 is being evaluated across oncology and rare disease indications, including glioblastoma multiforme (GBM), pancreatic cancer, and Primary CoQ10 Deficiency (PCQD). BPM31510 has received Orphan Drug Designation and Pediatric Rare Disease Designation from the U.S. Food and Drug Administration for multiple indications.

(Press release, BPGbio, MAY 28, 2026, View Source [SID1234666182])

On May 28, 2026 Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, reported that the Company will participate in the following investor events during the month of June.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details are as follows:

Jefferies Global Healthcare Conference
Date: Thursday, June 4, 2026
Time: 8:45 AM ET
Webcast Link: View Source

Goldman Sachs 47th Annual Global Healthcare Conference
Date: Tuesday, June 9, 2026
Time: 8:00 AM ET
Webcast Link: View Source

Virtual/Replay availability: Presentations will be archived on Compass’ Events page.

Compass’ management will be available for one-on-one meetings during all events. Interested investors should contact their respective representatives to request meetings.

(Press release, Compass Therapeutics, MAY 28, 2026, View Source [SID1234666181])

On May 28, 2026 RenovoRx, Inc. ("RenovoRx" or "the Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared drug-delivery device, reported that the U.S. Food and Drug Administration (FDA) recently granted RenovoRx Orphan Drug Designation (ODD) of oxaliplatin for the treatment of pancreatic cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The designation was issued by the FDA’s Office of Orphan Products Development pursuant to Section 526 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bb). Oxaliplatin is an approved and commonly used chemotherapy.

As RenovoRx continues to advance its therapeutic pipeline, it is simultaneously expanding commercialization of RenovoCath as a stand-alone device, driving adoption at leading cancer centers and building strategic and clinical collaborations that can support future revenue growth and broader platform use. RenovoCath, a patented FDA-cleared device, employs a dual-balloon infusion catheter for targeted delivery of therapeutic agents directly near a tumor.

This is RenovoRx’s second ODD in pancreatic cancer, and third designation in total, reflecting the Company’s differentiated approach to targeted intra-arterial drug-delivery using RenovoCath. RenovoRx previously received ODD for intra-arterial gemcitabine delivered via RenovoCath (known as IAG) in locally advanced pancreatic cancer (LAPC) and bile duct cancer. This designation for oxaliplatin, a platinum-based chemotherapy widely used in pancreatic cancer treatment, further supports the versatility of RenovoRx’s novel approach to delivering multiple therapeutic agents directly near the tumor site.

ODD carries meaningful regulatory and financial benefits, including:

Seven years of market exclusivity: Upon FDA approval of the designated indication (in this case, intra-arterial oxaliplatin for pancreatic cancer via RenovoCath), RenovoRx would be entitled to seven years of exclusive marketing rights, during which the FDA cannot approve the same drug for the same orphan indication by another sponsor.
Federal tax credit: A 25% tax credit on qualified clinical research expenses incurred in connection with the designated drug.
FDA application fee waiver: A waiver of the FDA application filing fee, which currently exceeds several million dollars for applications requiring clinical data.
Eligibility for orphan product development grants: Access to grant funding from the FDA’s Orphan Products Development grants program to support clinical development.
"Receiving a third ODD from the FDA is an important milestone as it provides additional validation of our strategy to build a multi-agent, targeted, drug-delivery oncology pipeline enabled by our patented RenovoCath device," said Shaun Bagai, Chief Executive Officer of RenovoRx. "Our differentiated technology is designed to deliver therapeutic agents intra-arterially across the arterial wall directly near the tumor site, with potential applications across multiple therapeutic agents and multiple cancer types. The FDA’s ODD of oxaliplatin not only expands our pipeline, but also provides valuable regulatory incentives, including seven years of potential market exclusivity and a waiver of FDA application fees that can total several million dollars. While we are laser focused on finishing our current Phase III clinical trial and advancing commercialization of RenovoCath as a standalone device, we remain committed to advancing our platform and exploring the full potential of targeted oxaliplatin delivery in patients diagnosed with difficult-to-treat cancers."

Pancreatic cancer remains one of the deadliest malignancies, with an estimated 67,530 new cases and more than 52,740 deaths expected in the United States in 2026, according to the American Cancer Society.[1] Despite advances in oncology, the disease is often diagnosed at a late stage in the majority of patients, and the five-year survival rate remains approximately 13%1, underscoring the profound unmet, yet urgent, medical need for new therapeutic approaches.

Oxaliplatin is a key component of FOLFIRINOX, one of the most widely used chemotherapy regimens for patients with advanced pancreatic cancer. RenovoRx is advancing a differentiated approach by delivering oxaliplatin directly near the tumor site using its RenovoCath device.

"This designation for intra-arterial oxaliplatin highlights the breadth of what RenovoCath may offer to pancreatic cancer patients," said Leesa Gentry, Chief Clinical Officer of RenovoRx. "Intra-arterial oxaliplatin may broaden the range of pancreatic cancer targets beyond LAPC that could benefit from localized drug-delivery with RenovoCath."

This ODD for intra-arterial oxaliplatin is separate from and in addition to RenovoRx’s existing ODD for IAG in LAPC and bile duct cancer, which also carries seven years of market exclusivity upon NDA approval by the FDA. RenovoRx’s TIGeR-PaC Phase III clinical trial evaluating IAG in LAPC continues to advance, with the Company anticipating notification of enrollment closure in June 2026 and final data readout in mid to late 2027.

(Press release, Renovorx, MAY 28, 2026, View Source [SID1234666180])

On May 28, 2026 RadioMedix, Inc., a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and cancer therapy, reported its upcoming participation at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting, taking place May 30 to June 2 in Los Angeles, California.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the meeting, RadioMedix leadership will participate in two sessions highlighting the Company’s work in targeted alpha therapy and lead-212 (²¹²Pb) radiopharmaceutical development.

Ebrahim S. Delpassand, M.D., Chief Executive Officer and Founder of RadioMedix, will participate in an Emerging Technology session focused on the production and clinical use of alpha emitters, where he will discuss the potential role of ²¹²Pb in radiopharmaceutical development.

Izabela Tworowska, Ph.D., MS.Pharm, Chief Scientific Officer, Co-Founder and Board Member of RadioMedix, will present during the Oncology: Discovery & Translational Meet-the-Author Session, highlighting preclinical evaluation of ²¹²Pb-RMX-VH-PKM, a second-generation LDLR-targeting radioconjugate co-developed with Vect-Horus for pancreatic ductal adenocarcinoma (PDAC). The presentation will include data on biodistribution, dose-dependent tumor response, survival, and preliminary tolerability in preclinical PDAC models.

In addition, Dr. Delpassand will participate in the 2026 IBA KOL Meeting, hosted by IBA RadioPharma Solutions during SNMMI week, on Saturday, May 30.

RadioMedix’s participation at SNMMI 2026 coincides with the Company’s 20th anniversary, marking a meaningful moment in its evolution as the broader radiopharmaceutical field continues to gain momentum. Since its founding in 2006, RadioMedix has helped shape the growth of radiopharmaceuticals through early clinical leadership in radioligand therapy, development of infrastructure across isotope supply and manufacturing, and contributions to foundational programs that have helped define the field.

"SNMMI has long been an important forum for scientific exchange and progress in nuclear medicine, making it a meaningful setting to share our latest work and mark RadioMedix’s 20-year journey," said Dr. Delpassand. "When we founded RadioMedix, our goal was to help bring the promise of targeted radiopharmaceuticals closer to patients with difficult-to-treat cancers. Over the past two decades, that mission has guided our work across discovery, isotope supply, manufacturing, and clinical development, and it continues to shape how we approach the future of targeted radiopharmaceutical innovation."

Today, RadioMedix continues to advance precision solutions in nuclear medicine with a focus on diagnostics and targeted therapies for cancers with high unmet need. The Company’s work spans radiopharmaceutical discovery and development, isotope generation, radiochemistry, translational research, and GMP production through the SPICA Center, its 27,000 sq. ft. radiopharmaceutical manufacturing facility.

"At RadioMedix, our scientific work has always been closely tied to patient need," said Dr. Tworowska. "Our participation at SNMMI this year is an opportunity to share progress from our team, engage with the broader nuclear medicine community, and recognize the importance of continued innovation in targeted radiopharmaceuticals. This year’s SNMMI meeting is especially meaningful for us as our company celebrates 20 years of innovation in radiopharmaceutical development and clinical translation."

Presentation Details
Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting

Emerging Technology Session
Session: ET03: Alpha 2: At-211 and Pb-212 (Non-CE)
Date: June 1, 2026
Session Time: 2:15 p.m. to 3:30 p.m. PT
Presentation: Pb-212: Clinical Use
Presentation Time: 2:25 p.m. to 2:35 p.m. PT
Location: 511ABC, Convention Center
Presenter: Ebrahim S. Delpassand, M.D., Chief Executive Officer and Founder, RadioMedix

Poster Presentation / Meet-the-Author Presentation
Title: Homing alpha-emitter therapy to pancreatic ductal cancer using 212Pb–labeled LDLR-targeting peptide
Session: MTA11: Oncology: Discovery & Translational Meet-the-Author Session
Date: June 2, 2026
Time: 11:30 a.m. to 12:15 p.m. PT
Location: Science Pavilion – South Hall GHJK (Convention Center)
Abstract Number: 262146
Screen: 43
Presenter: Izabela Tworowska, Ph.D., MS.Pharm, Chief Scientific Officer, Co-Founder and Board Member, RadioMedix

(Press release, RadioMedix, MAY 28, 2026, View Source [SID1234666179])